Clinical Trials Logo

Clinical Trial Summary

This is a phase II clinical study to evaluate the safety, tolerability and preliminary antitumor activity of LTC004 in patients with locally advanced or metastatic sarcoma;Enrollment of 10 evaluable subjects in Phase I. If ≥2 subjects experience objective remission or SD lasting >12 weeks, proceed to Phase II to enroll an additional 20 evaluable subjects to further evaluation of the safety and efficacy of LTC004


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT06384248
Study type Interventional
Source Letolab
Contact
Status Not yet recruiting
Phase Phase 1/Phase 2
Start date April 26, 2024
Completion date December 28, 2025